On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Although President Donald Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import taxes ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

As work progresses on an up-and-coming biologics plant in North Carolina, specialty pharma company Kyowa Kirin has completed ...

PhRMA is again turning up the heat on both big insurance companies and their pharmacy benefit managers (PBMs) in a new ad ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

Amid a massive reorganization of the federal healthcare infrastructure that has prompted pushback from biotech and healthcare ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...